EE170 A Cost-Effectiveness Analysis, with Public Healthcare Payers’ Perspective, of Oral Semaglutide Versus Luseogliflozin Hydrate for Patients with Type 2 Diabetes Mellitus in a Japanese Clinical Setting
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.439
https://www.valueinhealthjournal.com/article/S1098-3015(23)03569-6/fulltext
Title :
EE170 A Cost-Effectiveness Analysis, with Public Healthcare Payers’ Perspective, of Oral Semaglutide Versus Luseogliflozin Hydrate for Patients with Type 2 Diabetes Mellitus in a Japanese Clinical Setting
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03569-6&doi=10.1016/j.jval.2023.09.439
First page :
Section Title :
Open access? :
No
Section Order :
12465